Global Filgrastim Injection Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Filgrastim Injection Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Filgrastim Injection is used to decrease the chance of infection in people who have non myeloid cancer (cancer that does not involve the bone marrow) and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection). Filgrastim injection is also used to help increase the number of white blood cells, and decrease the length of time with fever in people with acute myeloid leukemia (AML; a type of cancer of the white blood cells) who are receiving treatment with chemotherapy medications. Filgrastim injection is also used in people who are undergoing bone marrow transplants, in people who have severe chronic neutropenia (condition in which there are a low number of neutrophils in the blood), and to prepare the blood for leukapheresis (a treatment in which certain blood cells are removed from the body. Filgrastim injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to the bone marrow. Filgrastim is in a class of medications called colony-stimulating factors. It works by helping the body make more neutrophils.
Filgrastim Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Filgrastim Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult Use and Pediatric Use are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Filgrastim Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Filgrastim Injection key manufacturers include Accord Healthcare, Teva Pharmaceuticals, Pfizer, Amgen Inc and Novartis AG, etc. Accord Healthcare, Teva Pharmaceuticals, Pfizer are top 3 players and held % sales share in total in 2022.
Filgrastim Injection can be divided into 300mcg/mL (vial), 480mcg/1.6 mL (vial), 300mcg/0.5mL (Prefilled Syringe) and 480mcg/0.8mL (Prefilled Syringe), etc. 300mcg/mL (vial) is the mainstream product in the market, accounting for % sales share globally in 2022.
Filgrastim Injection is widely used in various fields, such as Adult Use, Pediatric Use and Geriatric Use,, etc. Adult Use provides greatest supports to the Filgrastim Injection industry development. In 2022, global % sales of Filgrastim Injection went into Adult Use filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Filgrastim Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Accord Healthcare
Teva Pharmaceuticals
Pfizer
Amgen Inc
Novartis AG
Segment by Type
300mcg/mL (vial)
480mcg/1.6 mL (vial)
300mcg/0.5mL (Prefilled Syringe)
480mcg/0.8mL (Prefilled Syringe)
Adult Use
Pediatric Use
Geriatric Use
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Filgrastim Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Filgrastim Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Filgrastim Injection industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Filgrastim Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Filgrastim Injection introduction, etc. Filgrastim Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Filgrastim Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Filgrastim Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Filgrastim Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Adult Use and Pediatric Use are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Filgrastim Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Filgrastim Injection key manufacturers include Accord Healthcare, Teva Pharmaceuticals, Pfizer, Amgen Inc and Novartis AG, etc. Accord Healthcare, Teva Pharmaceuticals, Pfizer are top 3 players and held % sales share in total in 2022.
Filgrastim Injection can be divided into 300mcg/mL (vial), 480mcg/1.6 mL (vial), 300mcg/0.5mL (Prefilled Syringe) and 480mcg/0.8mL (Prefilled Syringe), etc. 300mcg/mL (vial) is the mainstream product in the market, accounting for % sales share globally in 2022.
Filgrastim Injection is widely used in various fields, such as Adult Use, Pediatric Use and Geriatric Use,, etc. Adult Use provides greatest supports to the Filgrastim Injection industry development. In 2022, global % sales of Filgrastim Injection went into Adult Use filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Filgrastim Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Accord Healthcare
Teva Pharmaceuticals
Pfizer
Amgen Inc
Novartis AG
Segment by Type
300mcg/mL (vial)
480mcg/1.6 mL (vial)
300mcg/0.5mL (Prefilled Syringe)
480mcg/0.8mL (Prefilled Syringe)
Segment by Application
Adult Use
Pediatric Use
Geriatric Use
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Filgrastim Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Filgrastim Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Filgrastim Injection industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Filgrastim Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Filgrastim Injection introduction, etc. Filgrastim Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Filgrastim Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices